Profile data is unavailable for this security.
About the company
Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of active pharmaceutical ingredients (APIs), formulation and development service. It is engaged in APIs, intermediates, formulations, new drug delivery systems, peptides / biotech products and specialty chemicals, and others. The Company supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Pemetrexed, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various international markets including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-Oncology API products include Ambroxol (Mucolytic agent), Tranexmic Acid and Ursodeoxycholic Acid. Its Injectable Dosage Forms include Myelodysplastic Syndrome, Breast Cancer, Multiple Myeloma, and more. Its Oral Solid Dosage Forms include Psoriasis, Prostate Cancer, Multiple Sclerosis, and others.
- Revenue in INR (TTM)11.51bn
- Net income in INR318.74m
- Incorporated1987
- Employees1.03k
- LocationShilpa Medicare LtdShilpa House#12-6-214/A1,, Hyderabad Road,RAICHUR 584135IndiaIND
- Phone+91 8 532238704
- Fax+91 8 532238876
- Websitehttps://www.vbshilpa.com/
More ▼
Mergers & acquisitions
| Acquired company | SHILPAMED:NSI since announced | Transaction value |
|---|---|---|
| Pilnova Pharma Inc | 87.13% | -- |
Data delayed at least 15 minutes, as of Jul 05 2024 11:15 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SeQuent Scientific Ltd | 13.70bn | -358.69m | 32.80bn | 478.00 | -- | 4.99 | 102.73 | 2.39 | -1.45 | -1.45 | 56.27 | 26.37 | 0.8925 | 2.19 | 4.05 | -- | -1.93 | 1.09 | -3.27 | 1.76 | 44.53 | 42.74 | -2.16 | 1.18 | 0.7602 | 0.1376 | 0.4062 | -- | -3.60 | 5.68 | 70.40 | -- | 6.96 | -- |
| Supriya Lifescience Ltd | 5.70bn | 1.19bn | 33.13bn | 392.00 | 27.81 | 4.06 | 24.55 | 5.81 | 14.80 | 14.80 | 70.87 | 101.31 | 0.655 | 2.21 | 5.81 | -- | 13.68 | 19.08 | 15.19 | 24.04 | 61.12 | 58.71 | 20.88 | 24.71 | 4.06 | 66.40 | 0.0067 | 2.88 | 23.74 | 15.47 | 32.56 | 24.75 | 83.79 | -- |
| Gufic BioSciences Ltd | 8.07bn | 861.36m | 36.55bn | 1.63k | 41.66 | 6.86 | 35.43 | 4.53 | 8.75 | 8.75 | 81.90 | 53.11 | 0.8258 | 2.03 | 3.01 | -- | 8.82 | 11.46 | 13.32 | 19.21 | 51.67 | 46.99 | 10.68 | 10.46 | 1.08 | 8.37 | 0.3847 | -- | 16.80 | 18.12 | 8.07 | 31.46 | 53.83 | 14.87 |
| Unichem Laboratories Ltd | 17.05bn | -704.74m | 37.56bn | 3.12k | -- | 1.59 | 87.84 | 2.20 | -10.02 | -10.02 | 238.88 | 335.54 | 0.5359 | 0.9995 | 2.84 | -- | -2.22 | -1.67 | -2.81 | -2.03 | 61.02 | 57.79 | -4.13 | -3.99 | 1.40 | -0.5733 | 0.0948 | -- | 26.94 | 7.64 | 65.15 | -- | -35.00 | -- |
| Hikal Ltd | 17.85bn | 696.00m | 45.20bn | 2.14k | 64.88 | 3.81 | 24.15 | 2.53 | 5.65 | 5.65 | 144.77 | 96.32 | 0.7325 | 2.66 | 3.60 | -- | 2.86 | 5.07 | 4.03 | 7.51 | 53.79 | 47.22 | 3.90 | 5.86 | 0.8761 | 2.65 | 0.4077 | 16.88 | -11.79 | 2.34 | -11.20 | -7.55 | 9.72 | 0.00 |
| Aarti Drugs Ltd | 25.29bn | 1.71bn | 50.97bn | 1.50k | 29.79 | 3.98 | 22.85 | 2.02 | 18.61 | 18.61 | 274.44 | 139.40 | 1.04 | 3.35 | 3.22 | -- | 7.07 | 9.73 | 10.98 | 15.74 | 33.65 | 24.96 | 6.79 | 8.25 | 1.05 | 7.91 | 0.3056 | -- | -6.90 | 10.13 | 3.07 | 13.82 | 24.96 | -- |
| Aarti Pharmalabs Ltd | 18.53bn | 2.17bn | 56.45bn | 1.40k | 26.02 | 3.21 | 19.46 | 3.05 | 23.94 | 23.94 | 204.45 | 193.89 | 0.7698 | 1.64 | 3.86 | -- | 9.01 | -- | 12.30 | -- | 44.90 | -- | 11.71 | -- | 1.01 | 18.17 | 0.1397 | -- | -4.76 | -- | 12.10 | -- | -- | -- |
| Orchid Pharma Ltd | 8.19bn | 915.95m | 58.00bn | 838.00 | 59.75 | 4.96 | 45.41 | 7.08 | 19.14 | 19.14 | 169.90 | 230.58 | 0.5897 | 1.97 | 3.99 | -- | 6.80 | -0.9734 | 8.80 | -1.40 | 40.87 | 43.32 | 11.53 | -2.40 | 2.03 | 4.68 | 0.1031 | -- | 23.05 | 6.43 | 73.59 | 5.84 | 57.79 | -- |
| Shilpa Medicare Ltd | 11.51bn | 318.74m | 64.56bn | 1.03k | 179.40 | 3.17 | 46.17 | 5.61 | 3.68 | 3.68 | 134.51 | 208.37 | 0.3841 | 1.23 | 3.21 | -- | 1.07 | 2.84 | 1.41 | 3.65 | 64.63 | 61.37 | 2.78 | 7.03 | 0.7671 | 1.41 | 0.3424 | -- | 9.66 | 9.44 | 198.15 | -22.26 | -9.26 | -- |
| Blue Jet Healthcare Ltd | 7.12bn | 1.64bn | 74.42bn | -- | 45.42 | 8.80 | 38.79 | 10.46 | 9.44 | 9.44 | 41.04 | 48.73 | 0.7409 | 2.46 | 3.42 | -- | 17.05 | -- | 21.25 | -- | 55.82 | -- | 23.01 | -- | 2.80 | 1,257.13 | 0.00 | -- | -1.30 | -- | 2.33 | -- | -- | -- |
| Sun Pharma Advanced Research Co Ltd | 755.50m | -3.87bn | 81.59bn | 407.00 | -- | 64.89 | -- | 108.00 | -11.93 | -11.93 | 2.33 | 3.87 | 0.1123 | -- | 3.13 | -- | -57.57 | -61.70 | -85.93 | -119.31 | 62.77 | 76.08 | -512.52 | -163.40 | -- | -245.33 | 0.3414 | -- | -68.36 | -16.20 | -73.96 | -- | 15.40 | -- |
| F D C Ltd | 19.43bn | 3.05bn | 83.90bn | 6.37k | 27.69 | 4.00 | 24.32 | 4.32 | 18.61 | 18.61 | 118.69 | 128.81 | 0.8077 | 1.83 | 16.19 | -- | 12.68 | 12.05 | 14.56 | 13.73 | 66.23 | 62.81 | 15.70 | 15.85 | 2.18 | 74.02 | 0.0097 | -- | 8.92 | 12.24 | 57.30 | 12.45 | 16.93 | -- |
| Marksans Pharma Ltd | 21.77bn | 3.14bn | 85.19bn | 1.40k | 27.13 | 4.13 | 21.89 | 3.91 | 6.93 | 6.93 | 48.11 | 45.57 | 0.894 | 1.88 | 5.01 | -- | 12.93 | 14.62 | 15.36 | 18.52 | 52.32 | 51.22 | 14.46 | 14.03 | 3.19 | 34.30 | 0.1048 | 6.66 | 17.56 | 16.84 | 17.80 | 32.62 | 73.86 | 64.38 |
| Procter & Gamble Health Ltd | 11.69bn | 2.14bn | 85.90bn | 1.41k | 40.16 | -- | 35.68 | 7.35 | 128.85 | 128.85 | 703.49 | -- | -- | -- | -- | 8,305,331.00 | -- | -- | -- | -- | 70.45 | -- | 18.31 | -- | -- | 400.33 | -- | -- | 10.34 | -- | 19.19 | -- | -- | -- |
| Strides Pharma Science Ltd | 40.51bn | -1.25bn | 86.08bn | 2.85k | -- | 4.05 | 119.30 | 2.12 | -13.86 | -7.93 | 445.06 | 231.29 | 0.6493 | 1.44 | 3.32 | -- | -2.38 | -1.68 | -4.43 | -2.97 | 59.50 | 52.74 | -3.67 | -3.36 | 0.64 | 1.07 | 0.5485 | -- | 9.83 | 13.21 | 43.57 | -- | -18.52 | -3.58 |
Data as of Jul 05 2024. Currency figures normalised to Shilpa Medicare Ltd's reporting currency: Indian Rupee INR
7.27%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ICICI Prudential Asset Management Co. Ltd.as of 31 May 2024 | 3.17m | 3.24% |
| Bandhan Asset Management Co. Ltd.as of 31 May 2024 | 1.52m | 1.56% |
| SBI Life Insurance Co. Ltd. (Investment Portfolio)as of 30 Apr 2024 | 1.10m | 1.13% |
| Dimensional Fund Advisors LPas of 06 Jun 2024 | 454.44k | 0.47% |
| WhiteOak Capital Asset Management Ltd.as of 31 May 2024 | 410.08k | 0.42% |
| SSgA Funds Management, Inc.as of 06 Jun 2024 | 190.62k | 0.20% |
| BlackRock Fund Advisorsas of 06 Jun 2024 | 109.03k | 0.11% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 May 2024 | 93.38k | 0.10% |
| Dimensional Fund Advisors Ltd.as of 30 Apr 2024 | 39.94k | 0.04% |
| American Century Investment Management, Inc.as of 06 Jun 2024 | 27.82k | 0.03% |
More ▼
Data from 31 Mar 2024 - 15 Jun 2024Source: FactSet Research Systems Inc.
